Evidence map›Paper›PMID 34389001›Full record

ArticleBMC musculoskeletal disorders2021

Thrombotic activation before and after total hip arthroplasty. A prospective cohort study.

Marta Burbul, Dariusz Tomaszewski, Anna Rogalska, Krzysztof Gawroński, Sławomir Literacki, Marcin Waśko

Open access · goldAbstract read
In one paragraph

Article in BMC musculoskeletal disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Marta BurbulDepartment of Traumatology and Orthopaedics, Military Institute of Medicine, Warsaw, Poland.
Dariusz TomaszewskiDepartment of Anesthesiology and Intensive Therapy, Military Institute of Medicine, Warsaw, Poland.
Anna RogalskaDepartment of Health Economics and Health Management, School of Health Sciences in Bytom, Medical University of Silesia in Katowice, Bytom, Poland.
Krzysztof GawrońskiInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Sławomir LiterackiDepartment of Laboratory Diagnostics, Military Institute of Medicine, Warsaw, Poland.
Marcin WaśkoDepartment of Radiology and Imaging, The Medical Center of Postgraduate Education, Warsaw, Poland. marcin@wasko.md.
Wojskowy Instytut Medycyny Lotniczej · PLInstytut Hematologii i Transfuzjologi · PLMedical University of Silesia · PLPostgraduate School of Molecular Medicine · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTotal hip arthroplasty (THA) causes acute blood loss. It may lead to a deficiency in coagulation factors, which, in turn, may lead to increased bleeding during the postoperative period.

methodsThirty patients (18 women) with a mean age of 67 years (range: 63-72 years) participated in this prospective diagnostic study. THA was performed without tranexamic acid administration in the perioperative period. Activities of clotting factors II, VIII, X, and fibrinogen concentration were evaluated before surgery, 6 hours after the procedure, 2, 4, and 6 days after the operation. All laboratory tests were performed using ACL TOP 500 CTS analyzer.

resultsNo thromboembolic complications were noted during hospitalization. Mean fibrinogen concentration was 366 mg/dL before surgery, which decreased to 311 mg/dL 6 hours after the operation and peaked at 827 mg/dL on the 4th day after the procedure. Activities of factors II and X decreased on the second and fourth days after surgery. Although the activity of factor VIII decreased after the procedure, it remained within the normal range. Increased baseline fibrinogen concentrations were observed in 6 out of 30 (20%) patients. Mean blood loss was 1332 mL (range, 183-2479 mL) and did not correlate with changes in clotting factor activities.

conclusionsIn patients undergoing THA, fibrinogen acts as an acute-phase protein. Activities of clotting factors II and X normalize within 6 days, and although the activity of factor VIII decreases, it remains within the normal range.

trial registrationThe study was pre-registered May 1st, 2020 on ClinicalTrials.gov.

Indexed as

Antifibrinolytic AgentsArthroplasty, Replacement, HipTranexamic AcidAgedBlood Loss, SurgicalFemaleHumansMiddle AgedProspective StudiesAntifibrinolytic AgentsTranexamic AcidBlood lossCoagulation factorsTotal hip arthroplastyVenous thromboembolism

Identifiers

PMID34389001
PMCPMC8364023
OpenAlexW3188500891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.